GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Endonovo Therapeutics Inc (OTCPK:ENDV) » Definitions » Revenue

Endonovo Therapeutics (Endonovo Therapeutics) Revenue

: $0.26 Mil (TTM As of Sep. 2023)
View and export this data going back to 2012. Start your Free Trial

Endonovo Therapeutics's revenue for the three months ended in Sep. 2023 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $0.26 Mil. Endonovo Therapeutics's Revenue per Share for the three months ended in Sep. 2023 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00.

Warning Sign:

Endonovo Therapeutics Inc revenue per share has been in decline over the past 3 years.

During the past 3 years, the average Revenue per Share Growth Rate was -86.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Endonovo Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 77.40% per year. The lowest was -86.90% per year. And the median was -83.70% per year.


Endonovo Therapeutics Revenue Historical Data

The historical data trend for Endonovo Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Endonovo Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.31 0.17 0.07 0.14

Endonovo Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.12 0.09 0.05 -

Competitive Comparison

For the Biotechnology subindustry, Endonovo Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Endonovo Therapeutics Revenue Distribution

For the Biotechnology industry and Healthcare sector, Endonovo Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Endonovo Therapeutics's Revenue falls into.



Endonovo Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Endonovo Therapeutics  (OTCPK:ENDV) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Endonovo Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Endonovo Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Endonovo Therapeutics (Endonovo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc is an us-based biotechnology company that focuses on the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary square waveform device. It is engaged in developing the Immunotronics platform which is non-implantable, a non-invasive medical device to target inflammatory conditions in vital organs; and the Cytotronics platform which uses Time-Varying Electromagnetic Fields technology for the creation of cell-based therapies. The company generates its revenue through its technology licensing and commercialization activities.
Executives
Alan Brian Collier director, 10 percent owner, officer: CEO 6320 CANOGA AVENUE, 15TH FLOOR, WOODLAND HILLS CA 91367
Michael Scott Mann 10 percent owner, officer: President 6320 CANOGA AVENUE, WOODLAND HILLS CA 91367

Endonovo Therapeutics (Endonovo Therapeutics) Headlines

From GuruFocus

Endonovo Announces Plans for Spin-off of Medical IP and Assets

By Value_Insider Value_Insider 12-15-2022

Endonovo Targets Dept. of Defense, VA & Federal Contracts

By Stock market mentor Stock market mentor 01-03-2023

Endonovo Launches Telehealth Initiative

By Value_Insider Value_Insider 12-13-2022

New Details on Endonovo's Spin-Off of SofPulse, Inc.

By Stock market mentor Stock market mentor 01-19-2023